



Freeze-drying of nanoparticles: Formulation, process and storage considerations[☆]

Wassim Abdelwahed^a, Ghania Degobert^{a,*}, Serge Stainmesse^b, Hatem Fessi^a

^a *Laboratoire d'Automatique et de Génie des Procédés (LAGEP) UMR-CNRS 5007 CPE Lyon, ISPB, Université Claude Bernard Lyon 1, 43, Boulevard du 11 Novembre 1918, 69622 Villeurbanne cedex, France*

^b *Conservatoire National des Arts & Métiers-Chaire des Techniques Pharmaceutiques, 292, rue Saint Martin, 75141 Paris, Cedex 03, France*

Received 14 September 2006; accepted 29 September 2006

Available online 6 October 2006

Abstract

Freeze-drying has been considered as a good technique to improve the long-term stability of colloidal nanoparticles. The poor stability in an aqueous medium of these systems forms a real barrier against the clinical use of nanoparticles. This article reviews the state of the art of freeze-drying nanoparticles. It discusses the most important parameters that influence the success of freeze-drying of these fragile systems, and provides an overview of nanoparticles freeze-drying process and formulation strategies with a focus on the impact of formulation and process on particle stability.

© 2006 Elsevier B.V. All rights reserved.

Keywords: Nanoparticles; Freeze-drying; Stability; Freezing; Cryoprotectant; Glass transition; Physical and chemical characterization; Formulation

Contents

1. Introduction	1689
2. Stability of nanoparticles	1690
2.1. Physical stability	1690
2.2. Chemical stability	1691
2.2.1. Effect of polymer type	1691
2.2.2. Effect of pH of the aqueous dispersion	1691
2.2.3. Chemical stability of entrapped drugs	1691
2.2.4. Effect of storage temperature	1692

[☆] This review is part of the *Advanced Drug Delivery Reviews* theme issue “2006 Supplementary Non-Thematic Collection”, Vol. 58/15, 2006.

* Corresponding author. Tel.: +33 472 431 874; fax: +33 472 431 874.

E-mail address: degobert@lagep.cpe.fr (G. Degobert).

3.	Freeze-drying process	1692
3.1.	Freezing step	1692
3.2.	Primary drying step	1693
3.3.	Secondary drying	1693
4.	Freeze-drying of nanoparticles	1693
4.1.	Importance of the formulation	1693
4.1.1.	Use of cryo and lyoprotectant	1693
4.1.2.	Importance of the interface composition (nanoparticle surface-dispersion medium)	1696
4.1.3.	Influence of entrapped drugs	1699
4.1.4.	Specific considerations concerning nanocapsules	1700
4.2.	Importance of the freeze-drying process	1701
4.2.1.	Freezing step	1702
4.2.2.	Annealing to optimize freeze-drying process	1703
4.2.3.	Primary drying step	1703
4.2.4.	Secondary drying step	1704
4.3.	Importance of storage	1704
5.	Physico-chemical characterization of freeze-dried product	1705
5.1.	Macroscopic aspect of freeze-dried product	1705
5.2.	Reconstitution time	1705
5.3.	Measurement of nanoparticles size and zeta potential after freeze-drying	1706
5.4.	Microscopic observation of freeze-dried product	1706
5.5.	Thermal analysis by differential scanning calorimetry (DSC)	1707
5.6.	Drug content determination	1707
5.7.	Powder surface analysis	1708
5.8.	Study of water sorption and determination of residual moisture	1708
6.	Application of freeze-drying in the domain of nanoparticles	1708
6.1.	To improve the stability of nanoparticles	1708
6.2.	To improve the drug association to nanoparticles	1709
6.3.	To produce solid dosage forms intended for various administration routes	1709
6.4.	To prepare core/shell nanoparticles	1709
6.5.	To obtain dry product suitable for analytical characterization	1710
7.	Conclusion	1710
	References	1710

1. Introduction

In the last decade, significant effort has been done to develop nanoparticles for drug delivery [1–5]. The colloidal systems offer a suitable means for delivering as well as small molecules than macromolecules such as proteins or peptides by either localized or targeted delivery to the tissue of interest. These systems in general can be used to provide targeted (cellular/tissue) delivery of drugs, to improve oral bioavailability, to sustain drug effect in target tissue, to solubilize drugs for intravascular delivery, and to improve the stability of therapeutic agents against enzymatic degradation [6–9].

Nanoparticles are submicron sized colloidal polymeric systems. According to the process used in

preparing nanoparticles, nanospheres or nanocapsules can be obtained [1–4,10]. Nanocapsules are vesicular systems in which a drug is confined inside a cavity surrounded by a polymeric membrane, whereas nanospheres are matrix systems in which a drug is dispersed throughout the particles.

The submicron size of nanoparticles offers a numerous advantages over microparticles. Nanoparticles have in general relatively higher intracellular uptake compared to microparticles. It was demonstrated that nanoparticle size of 100 nm showed 2.5 fold greater uptake compared to 1 μm and 6 fold higher uptake compared to 10 μm microparticles in Caco-2 cell line [8]. Similar results were obtained when these formulations of nano- and microparticles were tested

Download English Version:

<https://daneshyari.com/en/article/2072379>

Download Persian Version:

<https://daneshyari.com/article/2072379>

[Daneshyari.com](https://daneshyari.com)